The FDA asked Eli Lilly and Co. and Amylin Pharmaceuticals to conduct more safety studies on Byetta in light of reports linking the diabetes drug to pancreatitis. The companies, which co-market the drug, said additional studies are under way and so far have shown no heightened risk of pancreatitis in patients using Byetta.

Full Story:

Related Summaries